Investor Relations

AVEO Oncology (AVEO) is a biopharmaceutical company dedicated to advancing a broad portfolio of targeted therapeutics for oncology and other areas of unmet medical need. The company is focused on developing and commercializing its lead candidate tivozanib, a potent, selective, long half-life inhibitor of vascular endothelial growth factor 1, 2 and 3 receptors, in North America as a treatment for Renal Cell Carcinoma and other cancers. AVEO is leveraging multiple partnerships to develop and commercialize tivozanib in non-oncologic indications worldwide and oncology indications outside of North America, as well as to progress its pipeline of novel therapeutic candidates in cancer and cachexia (wasting syndrome).

NASDAQ | AVEO (Common Stock)
$0.62 + 0.01
Stock chart for: AVEO.O.  Currently trading at $0.62 with a 52 week high of $1.42 and a 52 week low of $0.56.
12/02/16 4:00 p.m. ET
Data Provided by Thomson Reuters

Press Releases

AVEO Announces Submission of Responses to the EMA Day 120 List of Questions for Marketing Authorization Application for Tivozanib in Renal Cell CarcinomaRead More
AVEO to Present at the 28th Annual Piper Jaffray Healthcare ConferenceRead More
AVEO Oncology Reports Third Quarter 2016 Financial Results and Provides Business UpdateRead More